Canaccord Genuity Group Reiterates C$6.50 Price Target for Knight Therapeutics (TSE:GUD)
Knight Therapeutics (TSE:GUD – Get Free Report) received a C$6.50 price objective from equities researchers at Canaccord Genuity Group in a research note issued on Friday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 13.84% from the stock’s previous close. […]
Knight Therapeutics (TSE:GUD – Get Free Report) received a C$6.50 price objective from equities researchers at Canaccord Genuity Group in a research note issued on Friday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 13.84% from the stock’s previous close. […]
